Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension
BACKGROUND: Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study.
OBJECTIVE: To reveal the pharmacogenetic predictors of the angioedema as a secondary side effect to enalapril in patients with essential arterial hypertension.
METHODS: The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing.
RESULTS: An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed.
CONCLUSION: The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
The International journal of risk & safety in medicine - 35(2024), 1 vom: 01., Seite 37-47 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sychev, Ivan V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69PN84IO1A |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JRS-230006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362391378 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362391378 | ||
| 003 | DE-627 | ||
| 005 | 20240304231946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JRS-230006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM362391378 | ||
| 035 | |a (NLM)37742663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sychev, Ivan V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study | ||
| 520 | |a OBJECTIVE: To reveal the pharmacogenetic predictors of the angioedema as a secondary side effect to enalapril in patients with essential arterial hypertension | ||
| 520 | |a METHODS: The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing | ||
| 520 | |a RESULTS: An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed | ||
| 520 | |a CONCLUSION: The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACE inhibitors | |
| 650 | 4 | |a adverse drug reaction | |
| 650 | 4 | |a angioedema | |
| 650 | 4 | |a enalapril | |
| 650 | 4 | |a hypertensive disease | |
| 650 | 7 | |a Enalapril |2 NLM | |
| 650 | 7 | |a 69PN84IO1A |2 NLM | |
| 650 | 7 | |a SLCO1B1 protein, human |2 NLM | |
| 650 | 7 | |a Liver-Specific Organic Anion Transporter 1 |2 NLM | |
| 700 | 1 | |a Denisenko, Natalia P |e verfasserin |4 aut | |
| 700 | 1 | |a Kachanova, Anastasiya A |e verfasserin |4 aut | |
| 700 | 1 | |a Lapshtaeva, Anna V |e verfasserin |4 aut | |
| 700 | 1 | |a Abdullaev, Sherzod P |e verfasserin |4 aut | |
| 700 | 1 | |a Goncharova, Ludmila N |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzaev, Karin B |e verfasserin |4 aut | |
| 700 | 1 | |a Sychev, Dmitry A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The International journal of risk & safety in medicine |d 1990 |g 35(2024), 1 vom: 01., Seite 37-47 |w (DE-627)NLM090578201 |x 1878-6847 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:1 |g day:01 |g pages:37-47 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JRS-230006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 1 |b 01 |h 37-47 | ||